Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:AKU CNSX:BUX NYSE:CRL TSE:EDT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkuminC$0.00C$0.16▼C$1.90C$37.20M0.157,202 shs12,903 shsBUXBiomark Diagnostics$0.00$0.00▼$0.00N/AN/AN/A11,500 shsCRLCharles River Laboratories International$230.590.0%$181.50$144.26▼$236.62$11.11B1.4836,719 shs845,133 shsEDTSpectral MedicalC$1.33-0.7%C$1.38C$0.77▼C$1.84C$393.18M0.82240752,479 shs20,829 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%0.00%BUXBiomark Diagnostics0.00%0.00%0.00%0.00%0.00%CRLCharles River Laboratories International0.00%+6.91%+24.21%+32.74%+46.40%EDTSpectral Medical0.00%-2.21%-5.67%-6.34%+64.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkuminC$0.00C$0.16▼C$1.90C$37.20M0.157,202 shs12,903 shsBUXBiomark Diagnostics$0.00$0.00▼$0.00N/AN/AN/A11,500 shsCRLCharles River Laboratories International$230.590.0%$181.50$144.26▼$236.62$11.11B1.4836,719 shs845,133 shsEDTSpectral MedicalC$1.33-0.7%C$1.38C$0.77▼C$1.84C$393.18M0.82240752,479 shs20,829 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%0.00%BUXBiomark Diagnostics0.00%0.00%0.00%0.00%0.00%CRLCharles River Laboratories International0.00%+6.91%+24.21%+32.74%+46.40%EDTSpectral Medical0.00%-2.21%-5.67%-6.34%+64.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUAkumin 0.00N/AN/AN/ABUXBiomark Diagnostics 0.00N/AN/AN/ACRLCharles River Laboratories International 2.69Moderate Buy$215.88-6.38% DownsideEDTSpectral Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BUX, CRL, EDT, and AKU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026CRLCharles River Laboratories International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/1/2026CRLCharles River Laboratories International Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$250.007/1/2026CRLCharles River Laboratories International BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$250.006/17/2026CRLCharles River Laboratories International Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$185.00 ➝ $220.006/16/2026CRLCharles River Laboratories International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026CRLCharles River Laboratories International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026CRLCharles River Laboratories International CLSASubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Outperform$167.00 ➝ $219.005/11/2026CRLCharles River Laboratories International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (E+)5/8/2026CRLCharles River Laboratories International Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$213.005/8/2026CRLCharles River Laboratories International EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$220.00(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUAkuminC$737.69M0.00N/A1.96C($2.86) per share0.00BUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$4.02B2.77$21.94 per share10.51$64.39 per share3.58EDTSpectral MedicalC$2.76M141.34C$0.02 per share82.50C($0.08) per share-16.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUAkumin-C$255.80M-C$3.80N/AN/AN/A-34.67%-483.86%0.47%N/ABUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International-$144.34M-$3.76N/A19.092.63-4.59%15.36%6.61%8/5/2026 (Estimated)EDTSpectral Medical-C$18.68M-C$0.13N/AN/AN/AN/A-973.97%-93.22%N/ALatest BUX, CRL, EDT, and AKU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026EDTSpectral MedicalN/A-C$0.01N/A-C$0.01N/AC$0.89 million5/7/2026Q1 2026CRLCharles River Laboratories International$1.96$2.06+$0.10-$0.30$977.46 million$995.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKUAkuminN/AN/AN/AN/AN/ABUXBiomark DiagnosticsN/AN/AN/AN/AN/ACRLCharles River Laboratories InternationalN/AN/AN/AN/AN/AEDTSpectral MedicalN/A1.45%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUAkumin266,886.350.121.03BUXBiomark DiagnosticsN/AN/AN/ACRLCharles River Laboratories International0.901.361.03EDTSpectral Medical26.030.610.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUAkumin30.27%BUXBiomark DiagnosticsN/ACRLCharles River Laboratories International98.91%EDTSpectral Medical0.03%Insider OwnershipCompanyInsider OwnershipAKUAkumin32.95%BUXBiomark DiagnosticsN/ACRLCharles River Laboratories International1.30%EDTSpectral Medical18.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUAkumin1,52770.18 millionN/ANot OptionableBUXBiomark DiagnosticsN/AN/AN/ANot OptionableCRLCharles River Laboratories International19,70048.17 million47.54 millionOptionableEDTSpectral Medical29293.42 millionN/ANot OptionableBUX, CRL, EDT, and AKU HeadlinesRecent News About These CompaniesSpectral Medical Announces U.S. FDA Filing of PMA Application for PMXJune 25, 2026 | financialpost.comFSpectral Medical Inc. Announces Results of Annual and Special Meeting of ShareholdersJune 9, 2026 | financialpost.comFSpectral Medical and Vantive Announce Topline 12 Month Follow-Up Results From Spectral’s Tigris TrialJune 4, 2026 | theglobeandmail.comThis Canadian stock has an upside of 147%, Research Capital saysMay 31, 2026 | cantechletter.comCSpectral Medical Announces PMA Submission to U.S. FDA for PMXMay 29, 2026 | financialpost.comFSpectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 8, 2026 | financialpost.comFSpectral Medical Inc.: Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate UpdateMarch 26, 2026 | finanznachrichten.deThis Canadian company is making advances in septic shock treatmentMarch 26, 2026 | cantechletter.comCSpectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate UpdateMarch 26, 2026 | theglobeandmail.comSpectral Medical Inc. (TSE:EDT) Is Expected To Breakeven In The Near FutureMarch 26, 2026 | finance.yahoo.comIs Spectral Medical a buy?March 25, 2026 | cantechletter.comCThis analyst loves Spectral MedicalMarch 2, 2026 | cantechletter.comCSpectral Medical Inc.: Spectral Medical Provides Update on PMA Submission Timing for PMX-20RFebruary 27, 2026 | finanznachrichten.deStocks in play: Spectral Medical IncFebruary 27, 2026 | ca.finance.yahoo.comThis Canadian biotech stock is very undervalued, analyst saysOctober 20, 2025 | cantechletter.comCSpectral Medical Inc. Files Base Shelf Prospectus and Revised AIFSeptember 29, 2025 | financialpost.comFSpectral Medical is a stock to buy now, this analyst saysAugust 26, 2025 | cantechletter.comCSpectral Medical Secures US$3 Million Funding to Advance Sepsis TreatmentAugust 25, 2025 | tipranks.comSpectral Medical eyes US approval of endotoxic septic shock deviceAugust 13, 2025 | finance.yahoo.comSpectral Medical and Vantive Announce Topline Results from Spectral’s Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic ShockAugust 12, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 20263 Stocks Doing the Heavy Lifting in Healthcare’s ReboundBy Jessica Mitacek | June 18, 2026BUX, CRL, EDT, and AKU Company DescriptionsAkumin TSE:AKUAkumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida. On October 22, 2023, Akumin Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.Biomark Diagnostics CNSX:BUXBioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.Charles River Laboratories International NYSE:CRL$230.59 -0.10 (-0.04%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$230.52 -0.06 (-0.03%) As of 07/2/2026 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Spectral Medical TSE:EDTC$1.33 -0.01 (-0.75%) As of 07/3/2026 03:51 PM EasternSpectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. The segments of the group are Spectral Medical Inc, which is the key revenue-generating segment that manufactures and sells its EAA diagnostic and certain proprietary reagents; Dialco Medical Inc segment; and Corporate. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
